Canaccord raised the firm’s price target on Ultragenyx (RARE) to $121 from $109 and keeps a Buy rating on the shares. The firm said they once again delivered a top-line beat which was driven by global Crysvita and Evkeeza demand.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE: